Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Dato-DXd approved in US for HR+ breast cancer | 20 Jan 2025 |
| Calquence combination approved in US for 1L MCL | 17 Jan 2025 |
| Total Voting Rights | 2 Jan 2025 |
| Dato-DXd NSQ NSCLC application withdrawn in EU | 24 Dec 2024 |
| Tagrisso approved in EU based on LAURA trial | 23 Dec 2024 |
| Directorate Change | 16 Dec 2024 |
| Imfinzi approved in US for limited-stage SCLC | 5 Dec 2024 |
| AstraZeneca appoints Iskra Reic EVP International | 4 Dec 2024 |
| Total Voting Rights | 2 Dec 2024 |
| Block listing Interim Review | 2 Dec 2024 |
| Truqap improved rPFS in advanced prostate cancer | 25 Nov 2024 |
| Director/PDMR Shareholding | 20 Nov 2024 |